Azenta Inc (AZTA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Azenta Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 28.10 $ — 48% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 2.3% failed
- More than 10% revenue growth is expected for the coming year 4.8% failed
- Share count grows by less than 3% a year -15.1% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 10.0% failed
- Gross margin at 40% or higher and without meaningful erosion 45.5% passed
- Goodwill from acquisitions does not grow faster than revenue 34.1% failed
- Net debt below twice EBITDA 230 m net cash passed
- Operating cash flow covers the profits of the last three years 363 m passed
- Return on capital at 15% or higher, or up versus two years ago -0.6% failed
- Insiders hold at least 10% or are net buyers 1.0% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 1.1% below the current price.
- Consensus
- Hold
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 09/30/2026 | 0.38 | 0.33 – 0.45 | 601 | -25.9% | 5 |
| 09/30/2027 | 0.61 | 0.55 – 0.67 | 630 | 62.4% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.10 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.24 | – | 147 | 4.00 | -7.50 | 30 | 22 |
| 2025: Q1 | -0.88 | – | 143 | 5.20 | -28.20 | 14 | 7 |
| 2025: Q2 | -1.16 | – | 144 | -0.20 | -36.70 | 26 | 15 |
| 2025: Q3 | 1.11 | – | 159 | 5.70 | 32.00 | 2 | -6 |
| 2025: Q4 | -0.34 | – | 149 | 0.80 | -10.40 | 21 | 15 |
| 2026: Q1 | -3.49 | – | 145 | 1.00 | -111.10 | 12 | 5 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 560 | 19 | -69 | -1.01 | 40 | 554 | 686 |
| 2017 | 528 | 18 | 63 | 0.89 | 96 | 608 | 767 |
| 2018 | 632 | 34 | 117 | 1.64 | 74 | 718 | 1,096 |
| 2019 | 781 | 55 | 29 | 0.40 | 91 | 1,139 | 1,517 |
| 2020 | 389 | -28 | 65 | 0.88 | 38 | 1,214 | 1,559 |
| 2021 | 514 | 4 | 111 | 1.49 | 150 | 1,325 | 1,820 |
| 2022 | 556 | -24 | -429 | -5.73 | -466 | 3,363 | 3,716 |
| 2023 | 665 | -82 | -14 | -0.22 | 6 | 2,535 | 2,886 |
| 2024 | 573 | -30 | -165 | -3.10 | 50 | 1,769 | 2,100 |
| 2025 | 594 | -11 | -56 | -1.22 | 72 | 1,727 | 2,060 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Azenta, Inc. bietet Lösungen zur Erforschung und Verwaltung biologischer und chemischer Verbindungsproben für die Life-Sciences-Branche in den USA, China, Großbritannien, im übrigen Europa, im asiatisch-pazifischen Raum und international an.
| Employees | 2,900 |
|---|---|
| Headquarters | Burlington, MA |
| Address | 200 Summit Drive, 01803 Burlington, United States |
| Phone | 888 229 3682 |
| Website | azenta.com |
| IPO Date | 2. Feb 1995 |
| ISIN | US1143401024 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John P. Marotta | President, CEO & Director | 1981 |
| Lawrence Y. Lin | Executive VP & CFO | 1977 |
| Ephraim Starr | Senior VP, General Counsel & Corporate Secretary | 1972 |
| Olga Pirogova | Senior VP & Chief HR Officer | 1974 |
| Ginger Zhou Ph.D. | Advisor | 1977 |
| Michael Paulo | VP, Chief Information & Digital Officer | – |
| Yvonne Perron | Vice President of Financial Planning & Analysis and Investor Relations | – |
| William E. Martin III | Senior Vice President & President of Multiomics | 1975 |
| Andrea O'Hara Ph.D. | Strategic Technical Specialist of Azenta Life Sciences | – |
| Alex Esmon | Vice President and General Manager of Sample Repository Solutions | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.